Pfizer to Present 45 Oncology Abstracts at ESMO 2026
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
OSAKA, Japan and CAMBRIDGE, Mass. — September 22, 2026 Takeda announced that new data from its oncology pipeline and...
TOKYO — September 18, 2026 Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products...
South San Francisco, California, August 31, 2026 IDEAYA Biosciences, Inc. announced the successful completion of a U.S. Food and...
Austin, Texas – August 27, 2026 Natera and Angiex have entered a new collaboration to assess treatment response to...
Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...
PRAGUE, Basel & Boston, Aug. 26, 2026 SOTIO Biotech announced that the U.S. Food and Drug Administration (FDA) has...
North Chicago, Illinois, USA, August 21, 2026 AbbVie has announced new clinical, translational and real-world research findings that will...
MAINZ, Germany, August 20, 2026 BioNTech SE is set to highlight major progress across its lung cancer clinical development...
Tokyo, Japan — August 17, 2026 Daiichi Sankyo and AstraZeneca announced positive topline results from the DESTINY-Lung04 Phase 3...
